- Home
- EKSO vs BTAI Comparison
EKSO vs BTAI Comparison
Compare EKSO & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EKSO
- BTAI
- Stock Information
- Founded
- EKSO 2005
- BTAI 2017
- Country
- EKSO United States
- BTAI United States
- Employees
- EKSO 66
- BTAI N/A
- Industry
- EKSO Medical/Dental Instruments
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- EKSO Health Care
- BTAI Health Care
- Exchange
- EKSO Nasdaq
- BTAI Nasdaq
- Market Cap
- EKSO 7.7M
- BTAI 8.3M
- IPO Year
- EKSO N/A
- BTAI 2018
- Fundamental
- Price
- EKSO $3.37
- BTAI $1.92
- Analyst Decision
- EKSO Strong Buy
- BTAI Buy
- Analyst Count
- EKSO 2
- BTAI 5
- Target Price
- EKSO $37.50
- BTAI $34.60
- AVG Volume (30 Days)
- EKSO 264.7K
- BTAI 291.4K
- Earning Date
- EKSO 07-28-2025
- BTAI 08-05-2025
- Dividend Yield
- EKSO N/A
- BTAI N/A
- EPS Growth
- EKSO N/A
- BTAI N/A
- EPS
- EKSO N/A
- BTAI N/A
- Revenue
- EKSO $17,544,000.00
- BTAI $1,852,000.00
- Revenue This Year
- EKSO $0.20
- BTAI $5.03
- Revenue Next Year
- EKSO $42.29
- BTAI $291.01
- P/E Ratio
- EKSO N/A
- BTAI N/A
- Revenue Growth
- EKSO N/A
- BTAI 5.47
- 52 Week Low
- EKSO $2.73
- BTAI $1.17
- 52 Week High
- EKSO $22.95
- BTAI $21.92
- Technical
- Relative Strength Index (RSI)
- EKSO 41.00
- BTAI 57.21
- Support Level
- EKSO $3.14
- BTAI $1.81
- Resistance Level
- EKSO $3.69
- BTAI $2.15
- Average True Range (ATR)
- EKSO 0.31
- BTAI 0.18
- MACD
- EKSO 0.09
- BTAI 0.01
- Stochastic Oscillator
- EKSO 59.81
- BTAI 60.40
About EKSO Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.